Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive …
N Yoshimura, S Kudoh, S Mitsuoka, N Yoshimoto… - Lung cancer, 2015 - Elsevier
Purpose Patients with advanced non-small cell lung cancer (NSCLC) harboring a sensitive
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …
[Retracted] The Use of Cytotoxic Drugs as First Line Chemotherapy for EGFR (+) Nonsquamous NSCLC: A Network Meta‐Analysis
D Li, M Li, H Li, P Shi, M Chen, T Yang - Disease Markers, 2023 - Wiley Online Library
Objective. To assess the use of cytotoxic drugs as first‐line chemotherapy for nonsquamous
non‐small‐cell lung cancer (NSCLC) with EGFR mutation. Method. This study uses the …
non‐small‐cell lung cancer (NSCLC) with EGFR mutation. Method. This study uses the …
[HTML][HTML] EGFR Exon 18 mutations in east Asian patients with lung adenocarcinomas: a comprehensive investigation of prevalence, clinicopathologic characteristics …
C Cheng, R Wang, Y Li, Y Pan, Y Zhang, H Li… - Scientific reports, 2015 - nature.com
Our aim was to investigate the clinical and pathologic characteristics of the epidermal growth
factor receptor (EGFR) exon 18 mutations in East Asian lung adenocarcinomas patients. A …
factor receptor (EGFR) exon 18 mutations in East Asian lung adenocarcinomas patients. A …
[HTML][HTML] Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
S Feng, Y Wang, K Cai, H Wu, G Xiong, H Wang… - PLoS …, 2015 - journals.plos.org
Background Epidermal growth factor receptor (EGFR) mutations occur in up to 50% of Asian
patients with non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients …
patients with non-small cell lung cancer (NSCLC). Treatment of advanced NSCLC patients …
Treatment of advanced non–small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international …
C Gridelli, F De Marinis, F Cappuzzo, M Di Maio… - Clinical lung cancer, 2014 - Elsevier
The availability of targeted drugs has made the assessment of the EGFR mutation and ALK
rearrangement critical in choosing the optimal treatment for patients with advanced non …
rearrangement critical in choosing the optimal treatment for patients with advanced non …
Acquired resistance in lung cancer
A Tulpule, TG Bivona - Annual Review of Cancer Biology, 2020 - annualreviews.org
The last decade has witnessed a transformation in the treatment of advanced-stage lung
cancer from a largely palliative approach to one where long-term durable remissions and …
cancer from a largely palliative approach to one where long-term durable remissions and …
[HTML][HTML] Targeted molecular treatments in non-small cell lung cancer: a clinical guide for oncologists
KT Bui, WA Cooper, S Kao, M Boyer - Journal of clinical medicine, 2018 - mdpi.com
Targeted molecular treatments have changed the way non-small cell lung cancer (NSCLC)
is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v …
is managed. Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), v …
[HTML][HTML] First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
H Zhang, J Chen, T Liu, J Dang, G Li - PLoS One, 2019 - journals.plos.org
Background It remains unknown which is the optimal first-line treatment regimen for patients
with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer …
with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer …
Current and future approaches in the management of non–small-cell lung cancer patients with resistance to EGFR TKIs
A Matikas, D Mistriotis, V Georgoulias, A Kotsakis - Clinical lung cancer, 2015 - Elsevier
Metastatic non–small-cell lung cancer carries a dismal prognosis. However, the recognition
of the predictive value of activating epidermal growth factor receptor (EGFR) mutations and …
of the predictive value of activating epidermal growth factor receptor (EGFR) mutations and …
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity
VL Damaraju, T Scriver, D Mowles, M Kuzma… - Clinical Cancer …, 2014 - AACR
Purpose: Combinations of tyrosine kinase inhibitors (TKI) with gemcitabine have been
attempted with little added benefit to patients. We hypothesized that TKIs designed to bind to …
attempted with little added benefit to patients. We hypothesized that TKIs designed to bind to …